QQ客服 官方微博 反馈留言

	OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice
	Delaloge, S.; Conte, P. F.; Im, S-A.; Senkus-Konefka, E.; Xu, B.; Domchek, S. M.; Masuda, N.; Li, W.; Tung, N.; Armstrong, A.
	2017
卷号	28
ISSN号	0923-7534
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6363538
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Delaloge, S.,Conte, P. F.,Im, S-A.,et al. OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice[J],2017,28.
APA	Delaloge, S..,Conte, P. F..,Im, S-A..,Senkus-Konefka, E..,Xu, B..,...&Robson, M..(2017).OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice.,28.
MLA	Delaloge, S.,et al."OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice".28(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。